[Jayne]

Hi Heather
Recruitment for the trial finished at the end of 2018, so I don’t think its possible to join it now I’m afraid.
Best Regards
Jayne

[Jayne]

I have not posted here before so apologies if I’m not doing it correctly!

My Son was/is on the Moxie Trial and few people have asked me about it so here’s a brief summary of what our Moxie consultant has explained in layman’s terms!
1. It works! (yay)
2. It not only halts progression, it has actually started to reverse it!
3. MFARS Scores in an FA patient would normally increase 1 to 2 points per year. Moxie has reduced MFARS score by 1.55 points so effectively reversing FA by 1 to 2 years!
(MFARS Scores test swallowing, speech, upper and lower limbs and stability)
4. The drug has to be approved by the FDA before it can be licenced (this is not a given, but is likely).
5. Because FA is an orphan disease, ie currently has no active treatment, it should be fast tracked by the FDA. Historically that is likely to take an absolute minimum of 6 months, but could be longer if there are questions.
6 FDA approval in America won’t automatically give it approval in Europe, UK etc and it will have to go through their approval processes too.
7. Several people have been on the expansion phase (active drug) for coming up to 6 months so new data should be available around December to see if there is a limit to how much Moxie can reverse FA (1.55 points) or whether the positive effect is cumulative and will keep on improving.
8. The medical meeting in December should also give more detailed information on secondary markers like whether Moxie has any impact on cardiac function etc
9. There are no obvious side effects to the drug.
10. Reata now plan to see if Moxie can help Alzheimer’s, Huntington’s Disease, Parkinson’s Epilepsy and Motor Neuron Disease.

Hope that helps 🙂